Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Fox Chase Offers Advanced Cancer Patients a Blueprint of Their Cancer Genes

Published: Wednesday, January 09, 2013
Last Updated: Wednesday, January 09, 2013
Bookmark and Share
Blueprint could help guide treatment for patients who have exhausted all other options.

Fox Chase Cancer Center, a National Cancer Institute-designated Comprehensive Cancer Center, is now offering patients with advanced cancer a cutting-edge clinical test that will provide them with a unique blueprint of their cancer genes.

The new clinical test, known as CancerCode-45TM, evaluates an individual’s tumor for genetic alterations in a select group of 45 genes and gives physicians the opportunity to look at the alterations and be even more precise when choosing a course of treatment. The test is being offered through the Cancer Genome Institute at Fox Chase—one of only a few centers in the nation to offer such pioneering technology in cancer molecular diagnostics.

“Gaining insight like this into the DNA of a specific tumor is the next step in transforming cancer care and prevailing over cancer,” says Michael V. Seiden, MD, PhD, president and CEO of Fox Chase. “We are very excited to be offering this innovative test at our Center and look forward to the ways it will enhance the care we provide our patients.”

Using leading-edge technology, physicians and scientists at Fox Chase are able to perform the CancerCode-45 test and analyze the genetic information in the DNA of a patient’s tumor to find changes that are crucial to supporting their cancer.  This genetic analysis will examine multiple alterations in 45 cancer-related genes and provide a report to the patient’s treating physician.

Prior to the CancerCode-45 test being performed, patients will need to see a Fox Chase physician to provide information about their background, medical history, current medications, and ability to perform daily activities. In addition, the physician will need to take a blood sample and a sample of the tumor (which can come from a previous surgery or biopsy that the patient might have had). It takes about 20 working days to get each patient’s test results.

“Not every patient will benefit from this test, but for some it could very well change their entire course of treatment and significantly prolong their life,” says Jeff Boyd, PhD, executive director of the Cancer Genome Institute at Fox Chase. “At the very least, the results may help physicians decide how to treat their patients with advanced cancer—whether by suggesting they use a particular type of drug or not use a particular type of drug or by allowing them to take part in clinical trials of new medications guided by their tumor’s genetic profile.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Scientists Find a New Way to Boost Common Cancer Drugs
Blocking a particular pathway in the cell makes it easier for drugs to annihilate tumors.
Wednesday, January 16, 2013
Researchers Develop a New Cell and Animal Model of Inflammatory Breast Cancer
The new model, developed by researchers at the Fox Chase Cancer Center, may provide scientists with a better understanding of the disease and help with developing effective intervention.
Tuesday, April 10, 2012
Fox Chase Researchers Uncover One Force behind the MYC Oncogene in Many Cancers
Researchers discover how embryonic gene, DLX5, may cause cancers in adults.
Monday, August 03, 2009
Inverted DNA Turns Quiet Developmental Gene into a Potent Driver of T-Cell Lymphoma
A gene crucial for embryonic development can quickly become a potent cancer promoter in adult mice after a genetic misalignment, according to researchers.
Friday, February 29, 2008
Scientific News
Big Genetics in BC: The American Society for Human Genetics 2016 Meeting
Themes at this year's meeting ranged from the verification, validation, and sharing of data, to the translation of laboratory findings into actionable clinical results.
Personality Traits, Psychiatric Disorders Linked to Specific Genomic Locations
Researchers have unearthed genetic correlations between personality traits and psychiatric disorders.
Genetics Control Regenerative Properties Of Stem Cells
Researchers define how genetic factors control regenerative properties of blood-forming stem cells.
Diabetes Missing Link Discovered
Researchers from the University of Auckland have shown that beta catenin plays a vital role in the control of insulin release from the pancreas.
Study Reveals New Role for Hippo Pathway in Suppressing Cancer Immunity
Hippo pathway signaling regulates organ size by moderating cell growth, apoptosis and stem cell renewal, but dysregulation contributes to cancer development.
Gene-Editing Improves Vision in Blind Rats
Scientists developed a targeted gene-replacement technique that can modify genes in both dividing and non-dividing cells in living animals.
Gene Editing Yields Tomatoes That Ripen Weeks Earlier
Research team develop method to make tomato plants flower and ripen fruit two weeks faster than current growth rates.
Exploring the Genome of the River Blindness Parasite
Researchers have decoded the genome of the parasite that causes the skin and eye infection known as river blindness.
Gene Therapy Maintains Clotting Factor for Hemophilia Patients
Following a single gene therapy dose, the highest levels of an essential blood clotting factor IX were observed in hemophilia B patients.
Unexpected Role for Epigenetic Enzymes in Cancer
Researchers use epigenetics to identify the role of an enzyme family as regulators of genetic message interpretation in yeast.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!